You Are Here: Home » Healthcare » Biotech Marketing

Data breach PR: How to survive your worst nightmare

There are two kinds of companies in this world: Those that have experienced a data breach, and those that will at some point in the future. At least that’s how seasoned cybersecurity experts approach risk assessment and mitigation plans. From a public-relations standpoint, once internal – or external – parties discover a data breach, a company’s immediate reaction will set the tone of the reportage. It’s a ...

Read more

Schwartz Ranks in Top Ten for Independent PR Firms!

Spring has sprung and with it, so has O’Dwyer’s annual ranking of independent public relations firms across the industry. Once again, Schwartz Communications was named among the top 10 independent PR firms out of 152 firms nationwide.  Additionally, Schwartz is ranked sixth among the top firms specializing in technology and healthcare respectively. Schwartz is proud to be ranked and recogni ...

Read more

Video Moves Beyond Consumer Healthcare PR to Technology, Life Sciences Communications

The Schwartz Digital team has been busy as of late creating videos and podcasts for our healthcare clients. It's great that these services have been so well received--I personally think it's indicative of widespread understanding among the types of companies Schwartz represents that there's way more to telling a story than issuing a press release and getting covered in BioWorld or Medical Device Daily. (Not ...

Read more

5 Reasons Why Your B2B Biotech Company Should Blog

Biotech companies have been slow to take advantage of blogging to communicate with their core audiences, but it's my impression that this situation is finally changing. Some of the interest I've been seeing among entrepreneurial life sciences companies is driven by an understanding of how blogging supports search engine optimization (SEO) efforts. There are more benefits to blogging than SEO, though, so her ...

Read more

Biotech, Pharmaceutical Companies Listen to Social Media

Yesterday the Boston Business Journal ran an overview, "Biotechs proceed with social-media caution," of the state of affairs in drug companies' use of Web 2.0 platforms like Facebook, Twitter and blogs.As you'd expect, this is an issue tracked carefully by every PR firm in Boston, San Francisco and other areas where the drug and medical device industries are concentrated.As we all know, companies ...

Read more

The Changing Media Landscape: What it Means for Healthcare Companies

When you convene a group of leading healthcare journalists, in front of a room full of healthcare PR professionals, sometimes there's no telling what you might hear. Journalists and PR folk, especially healthcare PR agency specialists, have a bit of a love hate relationship. We both need each other, for different reasons of course, and in light of the different media world we live in today, it's more critic ...

Read more

Some Simple yet Sage Advice on Communicating

Yesterday’s Xconomy Forum “Tomorrow’s Biotech: Innovators and Innovations” featured a first-rate slate of speakers and case studies. If you didn’t attend, Luke Timmerman’s Xconomy post provides a nice recap.The afternoon concluded with an engaging “fireside chat” keynote between biotech founding fathers Walter Gilbert and George Church moderated by Boston Univ ...

Read more

Making it in Massachusetts?

At the recent Massachusetts Biotechnology Counsel annual meeting, there was a lot of talk about what it will take for the industry to “Make it in Massachusetts”—a nod to a famous gubernatorial campaign slogan during the era of the state’s massive technology boom. Today, the Boston walls once plastered with “Make it in Massachusetts” bumper stickers are covered up by Shepa ...

Read more

PR Perspective from BayBio

Yesterday was the 20th BayBio event held in South San Francisco. In an era of declining interest in tradeshows, there were more than 700 attendees representing 400 companies. There is undeniable momentum in research as personalized medicine continues to show remarkable progress in fighting disease.  Naturally the economy’s impact to R&D and venture funding dominated the discussion. Buoyed by ...

Read more

Politics, Stem Cells and the FDA

 One of the more interesting recent medical stories to hit the mainstream media was the news that for the first time, the FDA has cleared the use of embryonic stem cells in human clinical trials. This particular trial will use a stem cell line developed by Geron, Inc. of Menlo Park, CA and will be implanted in people who have suffered acute spinal cord injury. As somebody who has actually seen the Gero ...

Read more